Bullous SLE: Response to methotrexate and relationship with disease activity

Lupus

Volumn 12, Issue 1, 2003, Pages 63-66

  Malcangi, G ^a   Brandozzi, G ^b   Giangiacomi, M ^c   Zampetti, M ^a   Danieli, M G ^a,d  

^a Istituto di Clinica Medica Generale   (Italy)

^b Divisione di Dermatologia   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d Polo Didattico Scientifico   (Italy)

Author keywords

Bullous manifestation; Methotrexate; Skin; Systemic lupus erythematosus

Indexed keywords

METHOTREXATE;

ADULT; ARTICLE; BULLOUS SKIN DISEASE; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; SKIN BIOPSY; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; METHOTREXATE; SKIN DISEASES, VESICULOBULLOUS;

EID: 0347298721     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu241cr     Document Type: Article

References (10)

1. Barton DD, Fine JD, Gammon WR, Sams WM Jr. Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa antigen. J Am Acad Dermatol 1986; 15: 369-373.
2. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993; 100: 28S-34S.
3. Yell JA, Allen J, Wojnarowska F, Kirtschig G, Burge SM. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921-928.
4. Hall RP, Lawley TJ, Smith HR et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 197: 165-170.
5. Gansage S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56: 382-385.
6. Bohem IB, Bohem GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanism. Rheumatol Int 1998; 18: 59-62.
7. Carneiro JRM and Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275-1279.
8. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10: 162-164.
9. Camisa C. Vesiculobullous systemic lupus erythematosus. A report of four cases. J Am Acad Dermatol 1988; 18: 93-100.
10. Ng YY, Chang IT, Chen TW, Liou HN, Yang AH, Yang WC. Concomitant lupus nephritis and bullous eruption in systemic lupus erythematosus. Nephrol Dial Transplant 1999; 14: 1739-1743.